J
Jialei Hu
Researcher at Centers for Disease Control and Prevention
Publications - 16
Citations - 320
Jialei Hu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Immunogenicity. The author has an hindex of 5, co-authored 14 publications receiving 216 citations.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Fengcai Zhu,Li-Hua Hou,Jingxin Li,Shipo Wu,Pei Liu,Gui-Rong Zhang,Yuemei Hu,Fan-Yue Meng,Junjie Xu,Rong Tang,Jie Zhang,Wen-Juan Wang,Lei Duan,Kai Chu,Qi Liang,Jialei Hu,Li Luo,Tao Zhu,Junzhi Wang,Wei Chen +19 more
TL;DR: The findings show that the high-dose vaccine is safe and robustly immunogenic and could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days.
Journal ArticleDOI
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Jingxin Li,Li-Hua Hou,Fan-Yue Meng,Shipo Wu,BS Yue-Mei Hu,BS Qi Liang,Kai Chu,BS Zhe Zhang,Jun-Jie Xu,Rong Tang,Wen-Juan Wang,ProfPhD Pei Liu,Jialei Hu,Li Luo,Rong Jiang,Fengcai Zhu,Wei Chen +16 more
TL;DR: The immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a homologous vector in healthy adults in China were analyzed.
Journal ArticleDOI
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Hongxing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wenling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Wei-Jin Huang,Fengcai Zhu,Fengcai Zhu +18 more
TL;DR: In this article, the authors report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults, in a phase 1 and phase 2 randomized, double-blind, and placebo-controlled trial.
Journal ArticleDOI
Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.
Kai Chu,Jialei Hu,Fan-Yue Meng,Jingxin Li,Li Luo,Jianjun Xu,Zhonghang Yuan,Zhiyong Li,Wangeng Chen,Lei Jiao,Yali Chang,Bingxiang Wang,Yuemei Hu +12 more
TL;DR: The data show that the 30 mcg formulation of the plague vaccine comprised of F1 and rV antigens showed good safety and immunogenicity in adults aged 18–55 y old and represents the preferred formulation for further clinical development.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hong-Xing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wen-Ling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Weijin Huang,Fengcai Zhu +17 more
TL;DR: In this article, the authors reported the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults in two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials.